SANO trial: What do patients with esophagus cancer value?
Krishan Jethw, Nina Niu Sanford and Vinay Prasad shared some insights on the SANO trial on X/Twitter:
“SANO-trial!! Been waiting for this one! Patients with esophagus ACA with cCR after CRT randomized to active surveillance vs. esophagectomy. Non-inferior OS and improved QoL with AS approach! Looking forward to manuscript to unpack the details.”
Source: Krishan Jethwa/X
“What do patients with esophagus cancer value?
In this study (n=100), patients were willing to accept a 16% decrement in 5-year OS for an opportunity to undergo an active surveillance regimen after neoadjuvant chemoRT. Therefore, with SANO showing similar OS and better QOL with organ preservation (deets/confirmation pending presentation in a few days), active surveillance should be a standard of care for patients with esophagus cancer achieving a complete response to chemoradiotherapy.”
Source: Nina Niu Sanford/X
“Incredible study. Patients willing to accept 16% loss of survival (aka massive) to lower getting surgery by 66%. Honestly, having seen the surgeries, me too! The real lesson is patients care about BIG OS diffs and not the piddly (2 mo PFS/ OS) that FDA permits from pharma.”
Source: Vinay Prasad/X
SANO trial results are published as “Patients’ preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer” by
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023